Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GX2W
|
|||
| Drug Name |
Nafithromycin
|
|||
| Synonyms |
UNII-75F74Y2R70; 75F74Y2R70; WCK 4873; Nafithromycin [INN]; CHEMBL4297519; (3R,31Z,3aS,4R,6R,8R,9R,10R,12R,15R,15aS)-15-Ethyl-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-N'-((1S)-1-(5-(pyridin-2-yl)-1,3,4-thiadiazol-2-yl)ethoxy)-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylohexopyranosyl)oxy)tetradecahydro-2; 1691240-78-4; 2H-Furo(2,3-C)oxacyclotetradecin-3-carboximidamide, 15-ethyltetradecahydro-8-methoxy-4,6,8,10,12,15a-hexamethyl-2,5,11,13-tetraoxo-N'-((1S)-1-(5-(2-pyridinyl)-1,3,4-thiadiazol-2-yl)ethoxy)-9-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyrano
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Community-acquired pneumonia [ICD-11: CA40.Z] | Phase 2 | [1] | |
| Company |
Wockhardt
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C42H62N6O11S
|
|||
| Canonical SMILES |
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)C)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)C(C(=O)O2)C(=NOC(C)C4=NN=C(S4)C5=CC=CC=N5)N)C
|
|||
| InChI |
1S/C42H62N6O11S/c1-13-28-42(9)30(29(39(53)58-42)35(43)47-59-25(7)36-45-46-37(60-36)26-16-14-15-17-44-26)22(4)31(49)20(2)19-41(8,54-12)34(23(5)32(50)24(6)38(52)56-28)57-40-33(51)27(48(10)11)18-21(3)55-40/h14-17,20-25,27-30,33-34,40,51H,13,18-19H2,1-12H3,(H2,43,47)/t20-,21-,22-,23+,24-,25+,27+,28-,29-,30+,33-,34-,40+,41-,42-/m1/s1
|
|||
| InChIKey |
RLFCSBSRGRJFRO-QAOQTAGDSA-N
|
|||
| CAS Number |
CAS 1691240-78-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02903836) Phase II Study of Oral Nafithromycin in CABP. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.